The Federal Trade Commission has sued the three largest pharmacy benefit managers (PBMs) for engaging in anticompetitive practices related to insulin, which has led to inflated prices for the medication. The FTC alleges that PBMs use restrictive formularies and demand high rebates from drug manufacturers, contributing to the increase in insulin costs. The lawsuit aims to reduce costs for all patients taking insulin. While the PBMs defend themselves, the FTC’s legal expert believes that the momentum favors the FTC in this case. The outcome of the lawsuit could result in changes to PBM practices and lower drug prices for consumers.
Source link
The FTC Is Suing PBMs Over Insulin Prices. Will It Be Successful?
